Warden Charles M 4

What Happened
Charles M. Warden, a director of Ocular Therapeutix, was granted awards on June 10, 2026 totaling 58,000 shares/RSU-equivalents (14,000 shares and 44,000 derivative awards) at $0.00 per share (total reported cash consideration $0). The grants are awards (code A) under the company's 2021 Stock Incentive Plan and convert to common stock upon vesting.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely; Form 4 due within two business days).
• Reported price: $0.00 per share; total cash paid reported as $0 (these are compensatory awards).
• Award amount: 14,000 shares + 44,000 derivative awards = 58,000 RSU-type awards.
• Vesting: Per footnotes, RSUs vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders, subject to continued board service.
• Shares owned after transaction: not specified in the provided filing.
• Footnotes: F1 describes that each RSU represents a right to one share; F2 reiterates the 100% vesting-on-year-one schedule (applies to the reported awards).
• No sale or purchase on the open market—this is a compensation grant.

Context
These awards are typical director compensation and will convert to shares only upon vesting; they are not an immediate purchase or sale. Such grants compensate service and don't by themselves indicate a trading signal or change in insider sentiment.